PET imaging of cholinergic deficits in rats using [ 18F]fluoroethoxybenzovesamicol ([ 18F]FEOBV)

NeuroImage

Volumn 62, Issue 1, 2012, Pages 555-561

  Parent, Maxime ^a,c   Bedard, Marc Andre ^a,b   Aliaga, Antonio ^b   Soucy, Jean Paul ^b   Landry St Pierre, Evelyne ^b   Cyr, Marilyn ^a   Kostikov, Alexey ^b   Schirrmacher, Esther ^b   Massarweh, Gassan ^b   Rosa Neto, Pedro ^b,c  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

192 IgG saporin; 18F fluoroethoxybenzovesamicol ( 18F FEOBV); Aging; Alzheimer's disease; Cholinergic neurotransmission; Molecular imaging; Neurodegeneration; Positron emission tomography; Vesicular acetylcholine transporter

Indexed keywords

FLUOROETHOXYBENZOVESAMICOL F 18; IMMUNOGLOBULIN G; RADIOLIGAND; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; HIPPOCAMPUS; IMAGE ANALYSIS; IN VIVO STUDY; MAGNOCELLULAR NUCLEUS; MALE; NEUROANATOMY; NONHUMAN; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; STEREOTACTIC PROCEDURE; TEMPORAL CORTEX;

AGING; ANIMALS; BRAIN; CHOLINERGIC NEURONS; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, LONG-EVANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS;

EID: 84861866582     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.04.032     Document Type: Article

References (42)

1. Canas P.M., Duarte J.M., Rodrigues R.J., Kofalvi A., Cunha R.A. Modification upon aging of the density of presynaptic modulation systems in the hippocampus. Neurobiol. Aging 2009, 30(11):1877-1884.
2. De Bartolo P., Gelfo F., Mandolesi L., Foti F., Cutuli D., Petrosini L. Effects of chronic donepezil treatment and cholinergic deafferentation on parietal pyramidal neuron morphology. J. Alzheimers Dis. 2009, 17(1):177-191.
3. Dournaud P., Delaere P., Hauw J.J., Epelbaum J. Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Neurobiol. Aging 1995, 16(5):817-823.
4. Efange S.M. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J. 2000, 14(15):2401-2413.
5. Fuhrmann G., Durkin T., Thiriet G., Kempf E., Ebel A. Cholinergic neurotransmission in the central nervous system of the Snell dwarf mouse. J. Neurosci. Res. 1985, 13(3):417-430.
6. Giboureau N., Emond P., Fulton R.R., Henderson D.J., Chalon S., Garreau L., et al. Ex vivo and in vivo evaluation of (2R,3R)-5-[(18)F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter. Synapse 2007, 61(12):962-970.
7. Gifford A.N., Park M.H., Kash T.L., Herman L.M., Park E.H., Gatley S.J., et al. Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362(4-5):413-418.
8. Gilmor M.L., Nash N.R., Roghani A., Edwards R.H., Yi H., Hersch S.M., et al. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. J. Neurosci. 1996, 16(7):2179-2190.
9. Henderson J.M., Carpenter K., Cartwright H., Halliday G.M. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 2000, 123(Pt. 7):1410-1421.
10. Hirano S., Shinotoh H., Shimada H., Aotsuka A., Tanaka N., Ota T., et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain 2010, 133(Pt. 7):2058-2068.
11. Ichikawa T., Ajiki K., Matsuura J., Misawa H. Localization of two cholinergic markers, choline acetyltransferase and vesicular acetylcholine transporter in the central nervous system of the rat: in situ hybridization histochemistry and immunohistochemistry. J. Chem. Neuroanat. 1997, 13(1):23-39.
12. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27(9):1533-1539.
13. Kilbourn M.R., Hockley B., Lee L., Sherman P., Quesada C., Frey K.A., et al. Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. Nucl. Med. Biol. 2009, 36(5):489-493.
14. Kovalenko N.Y., Matsievskii D.D. Role of cholinergic structures in individual resistance of rat circulatory system to posthemorrhagic hypoxia. Bull. Exp. Biol. Med. 2005, 140(2):177-180.
15. Landry St-Pierre E., Rosa Neto P., Massarweh G., Aliaga A., Mzengeza S., Bedard M.A., et al. Distribution of [18F]-FEOBV in rat: a promising tracer for imaging cholinergic innervation densities. Can. J. Neurol. Sci. 2008, 35(1):S46.
16. Landry St-Pierre E., Rosa Neto P., Massarweh G., Aliaga A., Mzengeza S., Bedard M.A., et al. Plasma chromatographic profile of [18F]-FEOBV in rat: results and implications for clinical applications. Can. J. Neurol. Sci. 2008, 35(1):S46-S47.
17. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10(5):740-747.
18. Mazere J., Prunier C., Barret O., Guyot M., Hommet C., Guilloteau D., et al. In vivo SPECT imaging of vesicular acetylcholine transporter using [(123)I]-IBVM in early Alzheimer's disease. Neuroimage 2008, 40(1):280-288.
19. Mesulam M.M., Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J. Comp. Neurol. 1988, 275(2):216-240.
20. Mesulam M.M., Mufson E.J., Levey A.I., Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 1983, 214(2):170-197.
21. Mesulam M.M., Geula C., Bothwell M.A., Hersh L.B. Human reticular formation: cholinergic neurons of the pedunculopontine and laterodorsal tegmental nuclei and some cytochemical comparisons to forebrain cholinergic neurons. J. Comp. Neurol. 1989, 283(4):611-633.
22. Mesulam M.M., Mash D., Hersh L., Bothwell M., Geula C. Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J. Comp. Neurol. 1992, 323(2):252-268.
23. Mufson E.J., Counts S.E., Perez S.E., Ginsberg S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev. Neurother. 2008, 8(11):1703-1718.
24. 18F]fluoroethoxy-benzovesamicol, a radiotracer for cholinergic neurons. J. Labelled Compd. Radiopharm. 1993, 33:583-591.
25. Mulholland G.K., Wieland D.M., Kilbourn M.R., Frey K.A., Sherman P.S., Carey J.E., et al. [18F]fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse 1998, 30(3):263-274.
26. Mzengeza S., Massarweh G., Rosa Neto P., Soucy J.-P., Bedard M.A. Radiosynthesis of [18F]FEOV and in vivo PET imaging of acetylcholine vesicular transporter in the rat. J. Cereb. Blood Flow Metab. 2007, 27(1S):10-17U.
27. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2009, Academic Press, San Diego. 6th ed.
28. Pizzo D.P., Waite J.J., Thal L.J., Winkler J. Intraparenchymal infusions of 192 IgG-saporin: development of a method for selective and discrete lesioning of cholinergic basal forebrain nuclei. J. Neurosci. Methods 1999, 91(1-2):9-19.
29. Pizzo D.P., Thal L.J., Winkler J. Mnemonic deficits in animals depend upon the degree of cholinergic deficit and task complexity. Exp. Neurol. 2002, 177(1):292-305.
30. Podruchny T.A., Connolly C., Bokde A., Herscovitch P., Eckelman W.C., Kiesewetter D.O., et al. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 2003, 48(1):39-44.
31. Prohovnik I., Perl D.P., Davis K.L., Libow L., Lesser G., Haroutunian V. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology 2006, 66(1):49-55.
32. Quirion R. Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release. J. Psychiatry Neurosci. 1993, 18(5):226-234.
33. Risbrough V., Bontempi B., Menzaghi F. Selective immunolesioning of the basal forebrain cholinergic neurons in rats: effect on attention using the 5-choice serial reaction time task. Psychopharmacology (Berl) 2002, 164(1):71-81.
34. Rubins D.J., Melega W.P., Lacan G., Way B., Plenevaux A., Luxen A., et al. Development and evaluation of an automated atlas-based image analysis method for microPET studies of the rat brain. Neuroimage 2003, 20(4):2100-2118.
35. Schafer M.K., Weihe E., Varoqui H., Eiden L.E., Erickson J.D. Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat. J. Mol. Neurosci. 1994, 5(1):1-26.
36. Sherman K.A., Friedman E. Pre- and post-synaptic cholinergic dysfunction in aged rodent brain regions: new findings and an interpretative review. Int. J. Dev. Neurosci. 1990, 8(6):689-708.
37. Soucy J.-P., Rosa Neto P., Massarweh G., Aliaga A., Schirrmacher E., Bedard M.A., et al. Imaging of cholinergic terminals in the non-human primate brain using 18F-FEOBV PET: development of a tool to assess cholinergic losses in Alzheimer's disease. Alzheimer Dis. Assoc. Disord. 2010, 6:S-286.
38. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006, 20(1):6-15.
39. Ward M. Biomarkers for Alzheimer's disease. Expert Rev. Mol. Diagn. 2007, 7(5):635-646.
40. Weihe E., Tao-Cheng J.H., Schafer M.K., Erickson J.D., Eiden L.E. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(8):3547-3552.
41. Wenk G.L., Stoehr J.D., Quintana G., Mobley S., Wiley R.G. Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats. J. Neurosci. 1994, 14(10):5986-5995.
42. Ypsilanti A.R., Girao da Cruz M.T., Burgess A., Aubert I. The length of hippocampal cholinergic fibers is reduced in the aging brain. Neurobiol. Aging 2008, 29(11):1666-1679.